KIF5B-ALK
Sign in to save this workspaceKIF5B-ALK · Variant type: fusion · Fusion partner: KIF5B (Kex24Aex20)
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Entrectinib | 99.6% | 0.4% | 93.69 |
| 2 | Lorlatinib | 99.4% | 0.6% | 97.24 |
| 3 | Brigatinib | 99.3% | 0.7% | 82.96 |
| 4 | Gilteritinib | 99.3% | 0.7% | 88.97 |
| 5 | Repotrectinib | 98.6% | 1.4% | 84.21 |
| 6 | Alectinib | 97.4% | 2.6% | 95.49 |
| 7 | Ceritinib | 97.0% | 3.0% | 95.44 |
| 8 | Crizotinib | 96.3% | 3.7% | 91.39 |
| 9 | Pralsetinib | 91.0% | 9.0% | 93.43 |
| 10 | Alpelisib | 88.7% | 11.3% | 97.22 |
| 11 | Sunitinib | 85.4% | 14.6% | 91.73 |
| 12 | Nintedanib | 84.8% | 15.3% | 90.23 |
| 13 | Bosutinib | 81.7% | 18.3% | 87.22 |
| 14 | Pacritinib | 60.6% | 39.4% | 88.64 |
| 15 | Defactinib | 49.8% | 50.2% | 92.68 |
| 16 | Ruxolitinib | 47.4% | 52.6% | 98.25 |
| 17 | Osimertinib | 46.4% | 53.6% | 97.24 |
| 18 | Fedratinib | 42.2% | 57.8% | 96.21 |
| 19 | Lazertinib | 37.6% | 62.4% | 97.47 |
| 20 | Axitinib | 33.3% | 66.7% | 93.23 |
| 21 | Fostamatinib | 29.4% | 70.6% | 96.74 |
| 22 | Neratinib | 28.7% | 71.3% | 93.18 |
| 23 | Tepotinib | 27.0% | 73.0% | 99.75 |
| 24 | Tenalisib | 27.0% | 73.0% | 97.98 |
| 25 | Darovasertib | 24.7% | 75.3% | 96.99 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Entrectinib | 99.6% | — | — |
| Lorlatinib | 99.4% | — | — |
| Brigatinib | 99.3% | — | — |
| Gilteritinib | 99.3% | — | — |
| Repotrectinib | 98.6% | — | — |
| Alectinib | 97.4% | — | — |
| Ceritinib | 97.0% | — | — |
| Crizotinib | 96.3% | — | — |
| Pralsetinib | 91.0% | — | — |
| Alpelisib | 88.7% | — | — |
| Sunitinib | 85.4% | — | — |
| Nintedanib | 84.8% | — | — |
| Bosutinib | 81.7% | — | — |
| Pacritinib | 60.6% | — | — |
| Defactinib | 49.8% | — | — |
| Ruxolitinib | 47.4% | — | — |
| Osimertinib | 46.4% | — | — |
| Fedratinib | 42.2% | — | — |
| Lazertinib | 37.6% | — | — |
| Axitinib | 33.3% | — | — |
| Fostamatinib | 29.4% | — | — |
| Neratinib | 28.7% | — | — |
| Tepotinib | 27.0% | — | — |
| Tenalisib | 27.0% | — | — |
| Darovasertib | 24.7% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 10.1ms